Evidence map›Paper›PMID 37602144›Full record

ArticleKidney medicine2023

Participant Perceptions in a Long-term Clinical Trial of Autosomal Dominant Polycystic Kidney Disease.

Sneha Amin, Irene Sangadi, Margaret Allman-Farinelli, Sunil V Badve, Neil Boudville, Helen Coolican, Susan Coulshed, Sheryl Foster, Mangalee Fernando, Imad Haloob and 14 more

Open access · goldAbstract read
In one paragraph

Article in Kidney medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 15 institutions in 2 countries.

Sneha AminMichael Stern Laboratory for Polycystic Kidney Disease, Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia.
Irene SangadiMichael Stern Laboratory for Polycystic Kidney Disease, Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia.
Margaret Allman-FarinelliSchool of Nursing, The University of Sydney, Sydney, Australia.
Sunil V BadveSt George Hospital, Sydney, Australia.
Neil BoudvilleSir Charles Gairdner Hospital, Perth, Australia.
Helen CoolicanPolycystic Kidney Disease Australia, Roseville, Australia.
Susan CoulshedNorth Shore Nephrology, Sydney, Australia.
Sheryl FosterDepartment of Radiology, Westmead Hospital, Western Sydney Local Health District, Sydney, New South Wales.
Mangalee FernandoDepartment of Renal Medicine, Prince of Wales Hospital, Sydney, Australia.
Imad HaloobDepartment of Renal Medicine, Bathurst Hospital, Bathurst, Australia.
David C H HarrisMichael Stern Laboratory for Polycystic Kidney Disease, Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia.
Carmel M HawleyAustralasian Kidney Trials Network, University of Queensland at Princess Alexandra Hospital, Brisbane, Australia.
Jane HoltDepartment of Renal Medicine, Wollongong Hospital, Wollongong, Australia.
Martin HowellSchool of Public Health, The University of Sydney, Sydney, NSW, Australia.
Karthik KumarGosford Nephrology, Gosford, Australia.
David W JohnsonAustralasian Kidney Trials Network, University of Queensland at Princess Alexandra Hospital, Brisbane, Australia.
Vincent W LeeMichael Stern Laboratory for Polycystic Kidney Disease, Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia.
Jun MaiDepartment of Renal Medicine, Liverpool Hospital, Southwestern Sydney Local Health District, Sydney, Australia.
Anna RanganSchool of Nursing, The University of Sydney, Sydney, Australia.
Simon D RogerRenal Research, Gosford, Australia.
Kamal SudDepartment of Renal Medicine, Nepean Kidney Research Centre, Nepean Hospital and Nepean Clinical School, The University of Sydney, Sydney, Australia.
Vicente TorresTranslational Polycystic Kidney Disease Center, Mayo Clinic, Rochester, MN.
Eswari VilayurDepartment of Nephrology, John Hunter Hospital, Newcastle, Australia.
Gopala K RanganMichael Stern Laboratory for Polycystic Kidney Disease, Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia.
The University of Sydney · AUGosford Hospital · AUTranslational Research Institute · AUWestmead Hospital · AUJohn Hunter Hospital · AUKidney Health Australia · AULiverpool Hospital · AUMayo Clinic · USPrince of Wales Hospital · AURoyal North Shore Hospital · AUSir Charles Gairdner Hospital · AUSt George Hospital · AUSydney Local Health District · AUWestmead Institute for Medical Research · AUWollongong Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rationale & Objective: The development of new therapies for autosomal dominant polycystic kidney disease requires clinical trials to be conducted efficiently. In this study, the factors affecting the recruitment and retention of participants enrolled in a 3-year randomized controlled trial in autosomal dominant polycystic kidney disease were investigated. Study Design: Qualitative study. Setting & Participants: All participants (N=187) were invited to complete a 16-item questionnaire at the final study visit of the primary trial. Participants were recruited to complete a semistructured interview using purposeful sampling according to age, self-reported gender, and randomization group. Analytical Approach: Descriptive statistics were used for demographic data and questionnaires. The interview transcripts underwent inductive thematic coding. Results: One hundred and forty-six of the 187 randomized participants (79%) completed the post-trial questionnaire, and 31 of the 187 participants (21%) completed the interview. Most participants (94%) rated their global satisfaction with the trial as high (a score of 8 or more out of 10). Altruism, knowledge gain, and access to new treatments were the main motivators for recruitment. The main reasons for considering leaving the study were concerns about the risk of intervention and family or work issues. Strategies that favored retention included flexibility in attending different study sites, schedule flexibility, staff interactions, and practical support with parking and reminders. The main burden was time away from work with lost wages, and burden associated with magnetic resonance imaging scans and 24-hour urine output collections. Limitations: The study population was restricted to participants in a single nondrug clinical trial, and the results could be influenced by selection and possible social desirability bias. Conclusions: Participants reported high levels of satisfaction that occurred as a function of the trial meeting participants' expectations. Furthermore, retention was a balance between the perceived benefits and burden of participation. Consideration of these perspectives in the design of future clinical trials will improve their efficiency and conduct. Plain-Language Summary: Advances in the clinical practice of autosomal dominant polycystic kidney disease (ADPKD) require affected individuals to voluntarily participate in long-term multicenter randomized controlled trials (RCTs). In this qualitative post hoc study of a 3-year RCT of increased water intake in ADPKD, altruism, knowledge gain, and access to a nondrug treatment positively influenced the decision to volunteer. Ongoing participation was enabled by building flexibility into the study protocol and staff prioritizing a participant's needs during study visits. Although participants completed the required tests, most were considered burdensome. This study highlights the importance of incorporating protocol flexibility into trial design; the preference for interventions with a low risk of adverse effects; and the urgent requirement for robust surrogate noninvasive biomarkers to enable shorter RCTs in ADPKD.

Indexed as

Autosomal dominant polycystic kidney diseaseclinical trialsparticipant experienceparticipant perspectivepatient-centered carequalitative researchtrial design

Identifiers

PMID37602144
PMCPMC10432794
OpenAlexW4382358317

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.